Supernus and Indivior signed an all-stock “merger of equals” to form a new CNS-focused company, combining portfolios across addiction, depression, attention-deficit/hyperactivity disorder, and Parkinson’s disease. The transaction is expected to close in 2026, creating a combined company that will operate under the Supernus name and includes multiple commercial products.